Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Anti-epileptic Agent [EPC]
Vigabatrin is a potent anti-epileptic agent (EPC) used as adjunctive therapy for refractory complex partial seizures and as monotherapy for infantile spasms. It acts as an irreversible inhibitor of GABA transaminase.
Name
Vigabatrin
Raw Name
VIGABATRIN
Category
Anti-epileptic Agent [EPC]
Drug Count
6
Variant Count
25
Last Verified
February 17, 2026
RxCUI
199521, 2642353, 250820, 2685217, 2685223, 2668482, 2047868, 860898, 860895
UNII
GR120KRT6K
About Vigabatrin
Vigabatrin is a potent anti-epileptic agent (EPC) used as adjunctive therapy for refractory complex partial seizures and as monotherapy for infantile spasms. It acts as an irreversible inhibitor of GABA transaminase.
Detailed information about Vigabatrin
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Vigabatrin.
The history of Vigabatrin is unique in the pharmaceutical landscape. While it was available in Europe and other global markets as early as the late 1980s, its approval in the United States by the FDA was delayed until 2009. This delay was primarily due to the discovery of a significant and potentially permanent risk of peripheral vision loss, which eventually led to the implementation of a Risk Evaluation and Mitigation Strategy (REMS) program. Despite these risks, Vigabatrin remains a critical tool in neurology, particularly for conditions like West Syndrome, where the benefit of seizure control often outweighs the risk of visual impairment. Healthcare providers typically reserve this medication for cases where other treatments have failed because of its significant toxicity profile.
To understand how Vigabatrin works, one must first understand the role of GABA in the central nervous system. GABA is the primary inhibitory neurotransmitter in the brain; it acts as a 'brake' on neuronal activity, preventing the over-excitation that leads to seizures. In patients with epilepsy, there is often an imbalance where excitatory signals overwhelm inhibitory ones.
Vigabatrin operates through a highly specific and irreversible mechanism of action. It targets the enzyme 4-aminobutyrate aminotransferase, also known as GABA transaminase (GABA-T). This enzyme is responsible for the catabolism (breakdown) of GABA into succinic semialdehyde. By binding covalently and irreversibly to GABA-T, Vigabatrin prevents the enzyme from functioning. This leads to a substantial and sustained increase in GABA concentrations within the synaptic cleft and the brain's interstitial fluid. Clinical studies using magnetic resonance spectroscopy have demonstrated that brain GABA levels can increase two- to three-fold following the administration of therapeutic doses of Vigabatrin. This elevated GABA level enhances inhibitory neurotransmission, thereby stabilizing the neuronal membrane and suppressing the initiation and spread of seizure activity. Because the inhibition is irreversible, the recovery of enzyme activity depends on the synthesis of new GABA-T enzymes, which explains why the drug's effects last much longer than its plasma half-life would suggest.
The pharmacokinetic behavior of Vigabatrin is relatively straightforward compared to other AEDs, as it does not undergo significant hepatic metabolism and lacks major protein binding.
Vigabatrin is specifically indicated for:
Off-label, it has been investigated for the treatment of certain substance use disorders (such as cocaine or methamphetamine addiction) due to its effect on the brain's reward system via GABA modulation, though these uses are not FDA-approved and remain experimental.
Vigabatrin is available in several formulations to accommodate different patient needs:
> Important: Only your healthcare provider can determine if Vigabatrin is right for your specific condition. Due to the risk of permanent vision loss, this drug is only available through a restricted distribution program called the VIGABATRIN REMS program.
For the treatment of Refractory Complex Partial Seizures, the standard starting dose for adults (17 years and older) is 500 mg taken twice daily (totaling 1,000 mg/day). Based on the patient's response and tolerability, the healthcare provider may increase the total daily dose in increments of 500 mg at weekly intervals. The recommended maintenance dose for adults is 3,000 mg per day (1,500 mg twice daily). Clinical trials have shown that doses higher than 3,000 mg/day do not generally provide significantly greater efficacy but do increase the risk of adverse effects, particularly visual field defects. If a patient does not show significant clinical improvement after a trial of 3,000 mg/day for 3 months, the medication should generally be discontinued.
The dosing for infantile spasms is weight-based. The typical starting dose is 50 mg/kg/day, divided into two doses. Depending on the clinical response, the dose may be titrated every 3 days up to a maximum of 150 mg/kg/day.
Healthcare providers usually assess the response within 2 to 4 weeks. If the spasms are not controlled within this timeframe, the drug is usually tapered and discontinued due to the high risk of toxicity.
Dosing for children is also weight-based and administered twice daily.
Since Vigabatrin is primarily eliminated by the kidneys, dose adjustments are mandatory for patients with renal insufficiency. According to clinical guidelines:
No specific dose adjustment is required for patients with hepatic impairment, as Vigabatrin does not undergo significant liver metabolism.
Elderly patients often have reduced renal function. Healthcare providers typically start at the lower end of the dosing range and monitor renal function (Creatinine Clearance) closely throughout treatment.
If you miss a dose of Vigabatrin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one. Frequent missed doses can increase the risk of breakthrough seizures.
Symptoms of Vigabatrin overdose may include severe drowsiness, dizziness, loss of consciousness, or bradycardia (slow heart rate). In the event of an overdose, seek emergency medical attention immediately. Treatment is primarily supportive, as there is no specific antidote for Vigabatrin. Because the drug is renally cleared, hemodialysis may be considered in extreme cases, though its effectiveness in overdose is not fully established.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as sudden discontinuation can trigger status epilepticus (continuous seizures).
In clinical trials, the most frequently reported side effects of Vigabatrin in adults include:
In pediatric patients (infants), the most common side effects include:
> Warning: Stop taking Vigabatrin and call your doctor immediately if you experience any of these.
The most critical long-term concern is Vigabatrin-Induced Retinal Toxicity. Research indicates that the risk of vision loss increases with the cumulative dose and duration of treatment. Some studies suggest that up to 30% to 50% of patients on long-term therapy may develop some degree of visual field constriction. Because this loss is permanent and cannot be reversed, patients must undergo regular ophthalmologic testing (perimetry) every 3 months during treatment.
Vigabatrin carries a FDA Boxed Warning for permanent vision loss. The warning states that Vigabatrin can cause permanent bilateral concentric visual field constriction in 30% or more of patients. The risk is higher with higher doses and longer durations, but it can occur at any time. Because of this risk, Vigabatrin should be used only in patients for whom the potential benefits outweigh the risk of vision loss. Vision should be tested at baseline, every 3 months during therapy, and 3 to 6 months after treatment ends. Vision loss may occur even if the patient has no symptoms.
Report any unusual symptoms to your healthcare provider immediately. Regular monitoring is the only way to detect early signs of toxicity.
Vigabatrin is a high-risk medication that requires intensive monitoring. It is not a first-line therapy for most patients. The most critical safety concern is the risk of permanent vision loss, which has led to its restricted distribution. Patients must be enrolled in the VIGABATRIN REMS (Risk Evaluation and Mitigation Strategy) program to receive this medication. This program ensures that both the prescriber and the patient are aware of the risks and that required vision testing is performed.
Vigabatrin commonly causes somnolence and dizziness. Furthermore, the risk of peripheral vision loss can significantly impair a person's ability to drive safely. Patients should not drive or operate heavy machinery until they know how the drug affects them and until their vision has been cleared by a specialist.
Alcohol should be avoided while taking Vigabatrin. Alcohol can potentiate the sedative effects of the medication, leading to extreme drowsiness, respiratory depression, and an increased risk of accidents or falls.
When discontinuing Vigabatrin in adults, the dose is typically reduced by 1,000 mg per day at weekly intervals. In infants being treated for infantile spasms, the taper schedule is determined by the physician based on the infant's weight and duration of treatment.
> Important: Discuss all your medical conditions, especially any history of vision problems, kidney disease, or depression, with your healthcare provider before starting Vigabatrin.
There are no absolute 'never-use' drug-drug contraindications for Vigabatrin based on metabolic pathways (since it doesn't use the CYP450 system). However, it is contraindicated in patients with a known hypersensitivity to the drug. From a clinical standpoint, it should not be used in combination with other drugs known to have significant retinal toxicity (such as hydroxychloroquine or ethambutol) unless absolutely necessary, as this may compound the risk of permanent blindness.
For each major interaction, the clinical consequence is usually either a loss of seizure control or an increase in toxicity (sedation or vision loss). Management involves frequent blood level monitoring of co-administered drugs and regular clinical assessments.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines and sleep aids.
There is no documented cross-sensitivity between Vigabatrin and other common anti-epileptic classes (like sulfonamides or hydantoins) because Vigabatrin's chemical structure as a GABA analog is unique. However, patients who have had severe reactions to other GABA-mimetic agents should be monitored closely.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney disease or mental health issues, before prescribing Vigabatrin. The decision to use this drug always involves a trade-off between seizure control and the risk of permanent vision loss.
Vigabatrin is classified as FDA Pregnancy Category C. Data from animal studies have shown that Vigabatrin has teratogenic effects, including an increased incidence of cleft palate at doses similar to those used in humans. There are no adequate and well-controlled studies in pregnant women. However, uncontrolled seizures during pregnancy also pose significant risks to both the mother and the fetus.
Vigabatrin is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants (including sedation and the theoretical risk of vision loss), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most healthcare providers recommend formula feeding while the mother is taking Vigabatrin to ensure infant safety.
Clinical studies of Vigabatrin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. However, because the drug is eliminated by the kidneys and elderly patients are more likely to have decreased renal function, dose selection should be cautious. Elderly patients are also at higher risk for the sedative and ataxic effects of the drug, which can lead to life-threatening falls.
Renal impairment significantly decreases the clearance of Vigabatrin.
Patients on hemodialysis may require further adjustments, as the drug is dialyzable.
Because Vigabatrin is not metabolized by the liver, no dose adjustment is typically required for patients with hepatic impairment. However, these patients should still be monitored for general tolerability.
> Important: Special populations require individualized medical assessment. Pediatric and geriatric patients, in particular, need frequent monitoring of both drug efficacy and potential toxicity.
Vigabatrin is a 'suicide inhibitor' of the enzyme GABA transaminase (GABA-T). Unlike competitive inhibitors that bind reversibly, Vigabatrin forms a covalent bond with the active site of the enzyme. This irreversible binding permanently disables the enzyme's ability to break down GABA (gamma-aminobutyric acid). Consequently, GABA levels in the brain rise significantly. This increase in the inhibitory neurotransmitter GABA results in a more stable neuronal environment, making it more difficult for the abnormal electrical discharges of a seizure to begin or spread. The effect on the enzyme is long-lasting; even after the drug is cleared from the blood, the inhibitory effect persists until the body synthesizes new GABA-T enzymes, a process that takes several days.
The pharmacodynamic effect of Vigabatrin is directly related to the rate of GABA-T enzyme resynthesis rather than the plasma concentration of the drug. Studies have shown that a single dose can inhibit GABA-T for several days. There is a clear dose-response relationship regarding the increase in brain GABA levels, but there is also a dose-response relationship regarding retinal toxicity. Tolerance to the anti-seizure effects is rare, but the CNS side effects (like sedation) often show some degree of tolerance after the first few weeks of therapy.
| Parameter | Value |
|---|---|
| Bioavailability | 60% - 100% |
| Protein Binding | < 10% |
| Half-life | 7 - 9 hours (Adults); 5.7 hours (Infants) |
| Tmax | 1 hour |
| Metabolism | Negligible (Not CYP-dependent) |
| Excretion | Renal 80% (Unchanged) |
Vigabatrin is classified as an Anti-epileptic Agent [EPC] and specifically a GABA-transaminase inhibitor. It is unique in this class, as other AEDs typically work on sodium channels (like carbamazepine), calcium channels (like ethosuximide), or by modulating GABA receptors (like benzodiazepines) rather than inhibiting the degradation of the neurotransmitter itself.
Medications containing this ingredient
Common questions about Vigabatrin
Vigabatrin is primarily used for two specific conditions: infantile spasms in babies aged 1 month to 2 years, and refractory complex partial seizures in adults and children 2 years and older. Because of its risk of permanent vision loss, it is not used as a first-line treatment but rather when other medications have failed. In infants, it is often a preferred choice for spasms caused by Tuberous Sclerosis. It works by increasing the levels of GABA, a calming chemical in the brain, to help prevent seizures. Your doctor will only prescribe it if the benefits of stopping the seizures outweigh the risks to your vision.
The most common side effects in adults include excessive sleepiness, dizziness, fatigue, and problems with coordination or walking. In infants, common side effects are often irritability, sleepiness, and an increase in respiratory infections like the common cold. Some patients also experience significant weight gain and tremors while taking this medication. Most of these side effects occur during the first few weeks as the body adjusts to the drug. However, any new or worsening symptoms should always be reported to your healthcare provider immediately.
No, you should avoid drinking alcohol while taking Vigabatrin. Alcohol can significantly increase the sedative effects of the medication, leading to dangerous levels of drowsiness and impaired coordination. This combination increases the risk of accidents, falls, and respiratory issues. Furthermore, alcohol can lower the seizure threshold, making the medication less effective at controlling your condition. Always consult your doctor before consuming any substances that affect the central nervous system.
Vigabatrin is generally not recommended during pregnancy unless the need for seizure control is absolute. It is classified as Category C, meaning animal studies have shown it can cause birth defects like cleft palate, but human data is limited. If you are pregnant or planning to become pregnant, you must have a detailed discussion with your neurologist about the risks. Sudden discontinuation of the drug during pregnancy can also be dangerous, so any changes must be managed by a medical professional. Many women are encouraged to join a pregnancy registry to help monitor the safety of the drug for future patients.
For infantile spasms, doctors usually look for a significant reduction in seizures within 2 to 4 weeks of starting treatment. If the spasms do not improve within this timeframe, the medication is typically considered ineffective and will be discontinued. For complex partial seizures in adults, it may take several weeks to reach the full maintenance dose through a gradual titration process. You may notice some improvement early on, but the full anti-seizure effect is usually assessed after 3 months of consistent use at the target dose. Always follow your doctor's specific timeline for evaluation.
No, you should never stop taking Vigabatrin suddenly. Abruptly discontinuing any anti-epileptic medication can cause a sudden increase in seizures or lead to status epilepticus, which is a life-threatening medical emergency. If the medication needs to be stopped—whether due to vision changes or lack of efficacy—your doctor will provide a schedule to slowly taper the dose over several weeks. This allows your brain to adjust gradually and minimizes the risk of withdrawal seizures. Always contact your healthcare provider if you have concerns that make you want to stop the drug.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular routine. Do not take two doses at once to make up for the one you missed, as this can increase the risk of side effects like extreme lethargy. Consistency is vital for maintaining steady levels of the drug in your brain to prevent seizures. If you find yourself missing doses frequently, talk to your pharmacist about tools like pill organizers or reminders.
Yes, weight gain is a known and relatively common side effect of Vigabatrin. In clinical trials, a significant percentage of patients reported an increase in body weight, which may be related to changes in appetite or metabolism. This weight gain can be substantial in some individuals and should be monitored by your healthcare provider. Maintaining a balanced diet and regular exercise may help manage this effect, but you should discuss any rapid or excessive weight changes with your doctor. They can help determine if the weight gain is related to the medication or another health issue.
Vigabatrin can be taken with many other medications because it is not processed by the liver's primary enzyme system, but some interactions do exist. For example, it can lower the levels of phenytoin in your blood, requiring a dose adjustment of that drug. It also increases the sedative effects of other anti-seizure drugs or benzodiazepines. You must provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. This allows them to check for potential interactions that could affect your safety or the drug's effectiveness.
Yes, Vigabatrin is available as a generic medication in both tablet and powder-for-oral-solution forms. The brand name version is Sabril. Generic versions are required by the FDA to have the same active ingredient, strength, and effectiveness as the brand-name drug. Both the brand and the generic versions are subject to the same strict VIGABATRIN REMS safety program requirements. Using the generic version can often be more cost-effective for patients while providing the same clinical benefits for seizure control.